Veterinary Oncology Market Size, Share & Trends Analysis Report By Animal Type (Canine, Feline), By Therapy (Radiotherapy, Surgery), By Cancer Type, By Region, And Segment Forecasts, 2025 - 2030
Veterinary Oncology Market Growth & Trends
The global veterinary oncology market size is expected to reach USD 3.11 billion in 2030 and is projected to grow at a CAGR of 12.08% from 2025 to 2030. Increasing prevalence of cancer in pets and demand for veterinary diagnostics are projected to drive the market over the forecast period.
Adoption of canine cancer registry globally to estimate cancer incidences is another driving factor for the market growth. According to frontiers in Veterinary Science in February 2019, the Swiss Canine Cancer Registry (SCCR) was used as a data source and was compiled for future comparative studies of canine and human cancers. This database is further helpful in mitigating the incidence of malignant tumors in the human population, thereby driving the market growth.
Researchers carrying out studies focused on veterinary oncology are further boosting the veterinary oncology market growth. For instance, University of Illinois in August 2017, carried out study that involves more precise detection of metastasis (spread of cancer through the body) for head and neck tumors in dogs. Moreover, the market players are also focusing on new product innovation and strategic collaborations. For instance, in 2018 AdvaVet, a subsidiary of Oasmia Pharmaceutical AB, developed XR17 technology, which is nanoparticle formulation based that makes a single Active Pharmaceutical Ingredient (API) or multiple APIs water soluble. It is a combination therapy and is also a standard treatment for a number of cancer diseases in pet animals.
Veterinary Oncology Market Report Highlights
- Increasing prevalence of cancer in companion animals, several clinical trial studies to evaluate the safety and effectiveness of cancer therapeutics for pets and technological advancements in veterinary oncology treatment are anticipated to create growth opportunities in the market.
- Chemotherapy accounted for the largest revenue share over the coming years, owing to its increasing adoption for pet cancer treatment either alone or in combination with other therapies.
- The canine segment held the largest revenue share of over 86.09% in 2024, increasing the population of dogs and high prevalence of cancer in dogs as compared to cats.
- North America held the dominant share as of 2024, due to the favorable government policies, new product launch by the companies, and huge investment for veterinary oncology treatment.
- Asia Pacific is anticipated to witness lucrative growth due to increasing focus on animal health and expenditure, increasing number of pet population being exposed to cancer, government focus on animal safety, and several initiatives to curb cancer cases in pet animals.
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased Database
- 1.3.2. GVR’s Internal Database
- 1.3.3. Secondary Sources
- 1.3.4. Primary Research
- 1.4. Information/Data Analysis
- 1.5. Market Formulation & Visualization
- 1.6. Data Validation & Publishing
- 1.7. Model Details
- 1.7.1. Commodity flow analysis
- 1.7.2. Global Market: CAGR Calculation
- 1.8. List of Secondary Sources
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
- Chapter 3. Veterinary Oncology Market Variable Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market
- 3.1.2. Ancillary Market
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing prevalence of cancer in pets
- 3.2.1.2. Increasing R&D in pet cancer therapy
- 3.2.1.3. Growing focus on animal safety
- 3.2.1.4. Growing uptake of pet insurance
- 3.2.1.5. Technological advancements in pet cancer treatment
- 3.2.1.6. Increase in pet population
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High cost of treatment
- 3.2.2.2. Adverse effects associated with therapies
- 3.2.2.3. Limited clinical evidence
- 3.2.3. Market Opportunity Analysis
- 3.2.4. Market Challenge Analysis
- 3.3. Veterinary Oncology Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitution
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political & Legal Landscape
- 3.3.2.2. Economic and Social Landscape
- 3.3.2.3. Technological landscape
- 3.3.2.4. Environmental Landscape
- 3.3.3. Regulatory Framework
- 3.3.4. Estimated Animal Population, by Key Countries and Key Species, 2018-2023
- 3.3.5. Product Pricing Analysis
- 3.3.6. COVID-19 Impact Analysis
- Chapter 4. Veterinary Oncology Market: Animal Type Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Veterinary Oncology Market Product Movement Analysis
- 4.3. Veterinary Oncology Market Size & Trend Analysis, By Animal Type, 2018 - 2030 (USD Million)
- 4.3.1. Canine
- 4.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.3.2. Feline
- 4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 4.3.3. Equine
- 4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 5. Veterinary Oncology Market: Therapy Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Veterinary Oncology Market Application Movement Analysis
- 5.3. Veterinary Oncology Market Size & Trend Analysis, By Therapy, 2018 - 2030 (USD Million)
- 5.3.1. Radiotherapy
- 5.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.3.1.2. Stereotactic Radiation Therapy
- 5.3.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.3.1.2.2. LINAC
- 5.3.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.3.1.2.3. Other Types
- 5.3.1.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.3.1.3. Conventional Radiation Therapy
- 5.3.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.3.2. Surgery
- 5.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.3.3. Chemotherapy
- 5.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.3.4. Immunotherapy
- 5.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 5.3.5. Other Therapies
- 5.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 6. Veterinary Oncology Market: Cancer Type Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Veterinary Oncology Market Animal Movement Analysis
- 6.3. Veterinary Oncology Market Size & Trend Analysis, By Cancer Type, 2018 - 2030 (USD Million)
- 6.3.1. Skin Cancers
- 6.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.2. Lymphomas
- 6.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.3. Sarcomas
- 6.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- 6.3.4. Others
- 6.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
- Chapter 7. Veterinary Oncology Market: Country Estimates & Trend Analysis, by animal type, therapy, & cancer type
- 7.1. Regional Dashboard
- 7.2. Veterinary Oncology Market Share, By Region, 2023 & 2030, USD Million
- 7.3. Regional Outlook
- 7.4. North America
- 7.4.1. North America Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competition Insights
- 7.4.2.3. U.S. Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competition Insights
- 7.4.3.3. Canada Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Competition Insights
- 7.4.4.3. Mexico Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competition Insights
- 7.5.2.3. UK Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competition Insights
- 7.5.3.3. Germany Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competition Insights
- 7.5.4.3. France Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Competition Insights
- 7.5.5.3. Italy Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Competition Insights
- 7.5.6.3. Spain Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Competition Insights
- 7.5.7.3. Denmark Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Competition Insights
- 7.5.8.3. Sweden Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Competition Insights
- 7.5.9.3. Norway Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competition Insights
- 7.6.2.3. Japan Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competition Insights
- 7.6.3.3. China Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Competition Insights
- 7.6.4.3. India Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Competition Insights
- 7.6.5.3. Australia Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Competition Insights
- 7.6.6.3. South Korea Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Competition Insights
- 7.6.7.3. Thailand Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Competition Insights
- 7.7.2.3. Brazil Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Competition Insights
- 7.7.3.3. Argentina Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.8. Middle East & Africa
- 7.8.1. Middle East & Africa Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Competition Insights
- 7.8.2.3. South Africa Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Competition Insights
- 7.8.3.3. Saudi Arabia Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Competition Insights
- 7.8.4.3. UAE Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Competition Insights
- 7.8.5.3. Kuwait Veterinary Oncology Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Market Participant Categorization
- 8.2. Participants Overview
- 8.3. Financial Performance
- 8.4. Product Benchmarking
- 8.5. Market Position Analysis, 2023 (Heat Map Analysis)
- 8.6. Strategy Mapping
- 8.6.1. MERGERS AND ACQUISITIONS
- 8.6.2. LAUNCH
- 8.6.3. PARTNERSHIPS & COLLABORATIONS
- 8.6.4. EXPANSION
- 8.6.5. OTHERS
- 8.7. Company Profiles
- 8.7.1. Elanco
- 8.7.1.1. Participant’s overview
- 8.7.1.2. Financial performance
- 8.7.1.3. Product Benchmarking
- 8.7.1.4. Strategic initiatives
- 8.7.2. Boehringer Ingelheim International GmbH
- 8.7.2.1. Participant’s overview
- 8.7.2.2. Financial performance
- 8.7.2.3. Product Benchmarking
- 8.7.2.4. Strategic initiatives
- 8.7.3. Zoetis
- 8.7.3.1. Participant’s overview
- 8.7.3.2. Financial performance
- 8.7.3.3. Product Benchmarking
- 8.7.3.4. Strategic initiatives
- 8.7.4. Elekta AB
- 8.7.4.1. Participant’s overview
- 8.7.4.2. Financial performance
- 8.7.4.3. Product Benchmarking
- 8.7.4.4. Strategic initiatives
- 8.7.5. PetCure Oncology
- 8.7.5.1. Participant’s overview
- 8.7.5.2. Financial performance
- 8.7.5.3. Product Benchmarking
- 8.7.5.4. Strategic initiatives
- 8.7.6. Accuray Incorporated
- 8.7.6.1. Participant’s overview
- 8.7.6.2. Financial performance
- 8.7.6.3. Product Benchmarking
- 8.7.6.4. Strategic initiatives
- 8.7.7. Varian Medical Systems, Inc. (parent company: Siemens Healthineers)
- 8.7.7.1. Participant’s overview
- 8.7.7.2. Financial performance
- 8.7.7.3. Product Benchmarking
- 8.7.7.4. Strategic initiatives
- 8.7.8. Virbac
- 8.7.8.1. Participant’s overview
- 8.7.8.2. Financial performance
- 8.7.8.3. Product Benchmarking
- 8.7.8.4. Strategic initiatives
- 8.7.9. Merck & Co., Inc.
- 8.7.9.1. Participant’s overview
- 8.7.9.2. Financial performance
- 8.7.9.3. Product Benchmarking
- 8.7.9.4. Strategic initiatives
- 8.7.10. Dechra Pharmaceuticals PLC
- 8.7.10.1. Participant’s overview
- 8.7.10.2. Financial performance
- 8.7.10.3. Product Benchmarking
- 8.7.10.4. Strategic initiatives
- 8.7.11. NovaVive Inc.
- 8.7.11.1. Participant’s overview
- 8.7.11.2. Financial performance
- 8.7.11.3. Product Benchmarking
- 8.7.11.4. Strategic initiatives
- 8.7.12. Ardent Animal Health, LLC (A BreakthrU Company)
- 8.7.12.1. Participant’s overview
- 8.7.12.2. Financial performance
- 8.7.12.3. Product Benchmarking
- 8.7.12.4. Strategic initiatives
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook